As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Pfenex

  • Friday's Range: $6.10-$6.56
  • 52-Week Range: $5.79-$24.41
  • Friday's Volume: 49,000
  • Three-Month Average Volume: 62,431

Pfenex  (PFNX - Get Report) , a clinical-stage biotechnology company, develops biosimilar therapeutics in the U.S. This stock closed up 4.1% to $6.51 in Friday's trading session.

From a technical perspective, Pfenex spiked higher on Friday right above some near-term support at $5.78 a share with lighter-than-average volume. This jump to the upside is now quickly pushing shares of Pfenex within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at Friday's intraday high of $6.56 to $6.60 a share and then above its 20-day moving average of $7.05 a share with high volume.

Traders should now look for long-biased trades in Pfenex long as it's trending above its recent low of $5.78 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 62,431 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.70 to $8, or even its 50-day moving average of $8.35 to possibly $8.90 a share.

InVivo Therapeutics

  • Friday's Range: $6.41-$6.73
  • 52-Week Range: $3.50-$17.87
  • Friday's Volume: 191,000
  • Three-Month Average Volume: 449,144

InVivo Therapeutics  (NVIV) , a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. This stock traded up 4.3% to $6.68 in Friday's trading session.

From a technical perspective, InVivo Therapeutics spiked notably higher on Friday right off its 50-day moving average of $6.39 a share with lighter-than-average volume. This jump to the upside is now quickly pushing shares of InVivo Therapeutics within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $6.88 to $7.10 a share and then above its 200-day moving average of $7.31 a share with high volume.

Traders should now look for long-biased trades in InVivo Therapeutics s as long as it's trending above its 50-day moving average of $6.39 a share or above its 20-day moving average of $6.12 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 449,144 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at just above $8 a share. Any high-volume move above $8 a share will then give this stock a chance to re-fill some of its previous gap-down-day zone from March that started at $9.15 a share.

Cara Therapeutics

  • Friday's Range: $6.14-$6.40
  • 52-Week Range: $4.26-$23.61
  • Friday's Volume: 627,000
  • Three-Month Average Volume: 735,244

Cara Therapeutics  (CARA - Get Report) , a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the U.S. This stock traded up 1.9% to $6.37 in Friday's trading session.

From a technical perspective, Cara Therapeutics spiked modestly higher on Friday back above its 50-day moving average of $6.31 a share with decent upside volume flows. This stock has been uptrending a bit over the last month, with shares moving higher off its low of $5.01 a share to its intraday high on Friday of $6.40 a share. During that move, shares of Cara Therapeutics have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed this stock within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels $6.60 to around $7 a share with high volume.

Traders should now look for long-biased trades in Cara Therapeutics as long as it's trending above its 20-day moving average of $5.78 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 735,244 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.35 to $8, or even $8.50 to $9 a share.

Genocea Biosciences

  • Friday's Range: $3.85-$4.08
  • 52-Week Range: $2.56-$16.18
  • Friday's Volume: 258,000
  • Three-Month Average Volume: 1.29 million

Genocea Biosciences  (GNCA) , a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. This stock traded up 2.8% to $3.98 share in Friday's trading session.

From a technical perspective, Genocea Biosciences spiked modestly higher on Friday right off its 20-day moving average of $3.85 a share with lighter-than-average volume. This small spike to the upside is now starting to push shares of Genocea Biosciences within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $4 to $4.20 a share and then above more resistance at $4.38 a share with high volume.

Traders should now look for long-biased trades in Genocea Biosciences as long as it's trending above its 20-day moving average of $3.85 a share or above more near-term support at $3.60 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.29 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $4.73 to around $5, or even $5.25 to $5.60 a share.

Caesars Entertainment

  • Friday's Range: $6.97-$7.52
  • 52-Week Range: $3.30-$10.61
  • Friday's Volume: 511,000
  • Three-Month Average Volume: 880,298

Caesars Entertainment  (CZR - Get Report)  provides casino-entertainment and hospitality services in the U.S. and internationally. This stock traded up 4.8% to $7.38 in Friday's trading session.

From a technical perspective, Caesars Entertainment ripped sharply higher on Friday right off its 20-day moving average of $7.01 a share with lighter-than-average volume. This stock has been uptrending a big over the last few weeks, with shares moving higher off its low of $6.66 a share to its intraday high on Friday of $7.52 a share. During that uptrend, shares of Caesars Entertainment have been making mostly higher lows and higher highs, which is bullish technical price action. This spike higher on Friday is now quickly pushing this stock within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out its 200-day moving average of $7.53 a share to some more key resistance at $7.70 a share with high volume.

Traders should now look for long-biased trades in Caesars Entertainment as long as it's trending above it 20-day moving average of $7.01 a share or above its 50-day moving average of $6.90 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 880,298 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.75, or even $9 to $9.50 a share.

Celldex Therapeutics

  • Friday's Range: $4.09-$4.34
  • 52-Week Range: $2.96-$29.94
  • Friday's Volume: 1.44 million
  • Three-Month Average Volume: 4.06 million

Celldex Therapeutics  (CLDX - Get Report) , a biopharmaceutical company, develops, manufactures and commercializes novel therapeutics for human health care in the U.S. This stock traded up 3.8% to $4.33 in Friday's trading session.

From a technical perspective, Celldex Therapeutics spiked notably higher on Friday right above its 50-day moving average of $4.03 a share with lighter-than-average volume. This jump to the upside is now quickly pushing shares of Celldex Therapeutics within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $4.38 to $4.46 a share with high volume.

Traders should now look for long-biased trades in Celldex Therapeutics as long as it's trending above its 50-day moving average of $4.03 a share or above its 20-day moving average of $3.91 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 4.06 million shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at $4.97 a share. Any high-volume move above $4.97 will then give this stock a chance to re-fill some of its previous gap-down-day zone from March that started near $8 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.